Atezolizumab selectively targets programmed death ligand 1 (PD-L1), thus reversing T-cell suppression, while bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), thus inhibiting angiogenesis and tumor growth [33,34,35]. The gene discussed is VEGFA; the disease is neoplasm.